Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2023-08-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司第二届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chengdu Lead Drug Development Co., Ltd. It details the approval of the company's 2023 semi-annual report and related documents, including a special report on the use of raised funds and a restricted stock incentive plan. The document references the 2023 semi-annual report and other reports published on the Shanghai Stock Exchange website but does not contain the actual financial statements or detailed financial data itself. It is a formal announcement of the Supervisory Board's meeting decisions and approvals rather than the report itself. The document length is 2431 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) because it is an official announcement of supervisory board resolutions and approvals related to reports and plans, not the reports themselves.
2023-08-22 Chinese
成都先导药物开发股份有限公司2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report". It covers the period from January 1, 2023 to June 30, 2023, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, earnings per share, and management discussion and analysis. It also contains sections on company overview, business model, industry analysis, and risk factors. The document length is about 15,000 characters, which is substantial and contains actual financial statements and substantive analysis. The document explicitly states it is a half-year report and includes financial statements and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
成都先导药物开发股份有限公司2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, earnings per share, and shareholder information for the half-year period. It also includes management discussion and analysis references and risk factors, typical of an interim or quarterly report. The document length is 3113 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
成都先导药物开发股份有限公司2023年限制性股票激励计划（草案）
Board/Management Information Classification · 95% confidence The document is a detailed plan titled "2023年限制性股票激励计划（草案）" which translates to "2023 Restricted Stock Incentive Plan (Draft)" for Chengdu Lead Drug Development Co., Ltd. It extensively discusses the purpose, principles, management, scope, stock source, quantity, allocation, effective period, grant date, vesting conditions, pricing, and implementation procedures of a restricted stock incentive plan. It references relevant laws and regulations such as the Company Law, Securities Law, and stock exchange rules. The document is not a financial report, earnings release, or regulatory filing but a comprehensive management and governance document related to stock-based employee incentives. This type of document fits best under "Board/Management Information (MANG)" as it involves management decisions and plans regarding stock incentives for executives and key personnel. The document length (15,000 characters) and content confirm it is the plan itself, not just an announcement or summary, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-08-22 Chinese
成都先导药物开发股份有限公司关于股东深圳市钧天投资企业（有限合伙）减持股份计划公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding a shareholder's plan to reduce their shareholding in the company. It details the shareholder's current holdings, the planned reduction amount, methods, timing, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or management discussions present. The document is a formal disclosure of a shareholding reduction plan by a significant shareholder, which fits the category of Transaction in Own Shares (POS). The document length is under 5,000 characters and contains detailed information about the share reduction plan rather than just announcing a report publication or regulatory filing. Therefore, the appropriate classification is POS with high confidence.
2023-07-24 Chinese
成都先导药物开发股份有限公司关于股东减持时间过半暨减持股份进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a shareholder share reduction plan, detailing the amounts and percentages of shares reduced by various shareholders over a specified period. It includes information about the shareholders, their holdings before and after the reduction, and the impact of the reduction on company control and governance. The document does not contain financial statements or detailed financial performance data. It is a regulatory disclosure about insider share transactions by significant shareholders, specifically about their share reduction activities. This fits the definition of a 'Transaction in Own Shares' filing, which reports on the company shareholders selling their shares. The document length is 3440 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2023-07-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.